FETAL CYSTIC HYGROMA ASSOCIATED WITH TERMINAL 2p25.1 DUPLICATION AND TERMINAL 3p25.3 DELETION: CYTOGENETIC, FLUORESCENT IN SITU HYBRIDIZATION AND MICROARRAY FAMILIAL CHARACTERIZATION OF TWO DIFFERENT CHROMOSOMAL STRUCTURAL REARRANGEMENTS
Stipoljev F, Barbalic M, Logara M, Vicic A, Vulic M, Zekic Tomas S, Gjergja Juraski R
*Corresponding Author: Feodora Stipoljev, Ph.D., Associate Professor, Cytogenetic Laboratory, Department of Obstetrics and Gynecology, Clinical Hospital “Sveti Duh,” Sveti Duh 64, 10000 Zagreb, Croatia. Tel.: +385-1371-2273. Fax: +385-1374-5534. E-mail: stipoljev@yahoo.com
page: 79

DISCUSSION

We have presented an extremely rare, prenatally diagnosed case of partial trisomy 2p25.3-p25.1 and partial monosomy 3p26.3-p25.3 of paternal origin. To date, only one study by Chen et al. [7] from 1996 reported a very similar unbalanced translocation involving partial 2p trisomy and partial 3p monosomy. Both parents were phenotypically normal and the mother was a balanced reciprocal translocation carrier 46,XX, t(2;3)(p25.3;p25). Prenatal sonographic findings included single umbilical artery, shortening of the long bones and hypertelorism, while 10-month follow-up revealed craniofacial dysmorphy, hypotonia, growth and mental retardation. In our case, the fetal karyotype showed an unbalanced translocation with a partial trisomy 2p25.1-pter, partial monosomy 3p25.3- pter, and balanced paracentric inversion of chromosome 3 with breakpoint sites in 3p13 and 3p25.3, both of paternal origin. The fetus had hypertelorism, low-set posteriorly rotated ears and cystic hygroma. Father is a carrier of two different structural rearrangements with a common breakpoint in 3p25.3. As the total number of breakpoint sites is three, it cannot be classified as a complex chromosomal rearrangement. The investigation of patients with apparently one type of balanced structural chromosomal abnormality can give unexpected findings of another apparently cryptic balanced rearrangement, which can be overcame with use of FISH analysis. Partial trisomy 2p has been published in more than 50 cases, mostly in unbalanced translocations with other chromosomes. The main clinical features referring to partial trisomy 2p25.3-p25.1 include developmental delay and craniofacial dysmorphia. Only few studies reported pure duplication of the 2p terminal region. Wahita et al. [8] described a patient with 2p25.1-pter duplication with trigonocephaly, hypertelorism, anteverted nares, external ear anomalies, exophthalmos, arachnodactyly and joint dysplasia, but without developmental delay. Roggenbuck et al. [9] reported a case of 3-year-girl with a significant psychomotor delay and dysmorphy including a prominent forehead, malar hypoplasia, and a prominent nose with a narrow alar base. Additionally, a long torax, a mild pectus carinatum deformity and scoliosisis, with long and slender extremities were found. She had a de novo pure partial trisomy 2p24.3-2pter. Bonaglia et al. [1] reported a familial 10.0 Mb inverted duplication 2p25.3-25.1 and 270 kb deletion of 2pter. Two children and their father exhibited mental retardation and craniofacial dysmorphia including hypertelorism, high forehead, low-set and irregular ears, thin upper lip and flat philtrum. The duplicated 10.5 Mb region 2p25.1p25.3 in our case contains 45 different genes, where 12 (ODC1, KLF11, RPS7, TPO, MYT1L, PXDN, RNASEH1, COLEC11, SOX11, ADAM 17, KIDINS220, TRAPPC12) are reported as OMIM morbid genes with different phenotypical implications. Coffin-Siris syndrome 9 (CSS9) or autosomal dominant mental retardation-27 (MRD27, MIM 615866) caused by a heterozygous mutation in the SOX11 gene, is usually accompanied by facial dysmorphia, growth deficiency and mild intellectual disability. Tsurusaki et al. [10] emphasized the importance of SOX11, which encodes SoxC group high mobility group (HMG) box-containing transcription factor as a downstream transcriptional factor of the PAX6 and BAF complex in brain development. Moreover, SOX11 and MYT1L were also duplicated in this as in our case. MYT1L is a member of myelin transcription factor 1 family, acting on neuronal differentiation. Disrupted function of one MYT1L allele on 2p25.3 by cryptic gene deletion, intragenic duplication, or point mutation will cause syndromic intellectual disability (mental retardation, autosomal dominant 39) in large number of such patients [11]. Bonaglia et al. [1] hypothesized that an increased expression of MYT1L product could lead to developmental difficulties associated with partial 2p trisomy. P Lund et al. [12] analyzed 132 fetuses with an increased nuchal translucency of >3.5 mm with chromosomal microarray. Among 12 fetuses with pathogenic copy number variants (CNV), one in whom the NT was measured 6.6 mm had a 46.0 Mb duplication of region 2p25.3-p21. Mother was a balanced translocation carrier. Lee et al. [3], described a fetus with cystic hygroma and unbalanced karyotype with additional chromosomal material on short arm of chromosome 9, designated as distal part of short arm of chromosome 2. Aviron-Goldring et al. [2] described a prenatally diagnosed case of partial trisomy 2pter resulting from an unbalanced karyotype 46,XY,der(21) t(2;21)(p24;p11.1) of de novo origin. The pregnancy was terminated at 24 weeks’ gestation, and autopsy revealed high forehead, hypertelorism, small nose with depressed nasal bridge, thin upper lip, epicantal folds, micrognatia, low-set slightly rotated ears, short neck with excess skin, proximally placed thumbs, and urogenital anomalies (mildly distended ureters and enlarged kidneys, hypoplastic testes). Thangavelu et al. [13] reported a prenatal case with a terminal duplication 2p25.3-p22 and anencephaly at 16.7 weeks’ gestation. Marlet et al. [14] described a prenatal case of de novo inverted duplication 2p21p25.3 size of 43.75 Mb with present interstitial telomeric sequences at the breakpoint 2p21 and a tetralogy of Fallot. Nonspecific ultrasound findings described in previous reports regarding prenatal findings in partial 2p trisomy included increased NT/cystic hygroma, as in our case, as well as heart defect, anencephaly, hypertelorism, low-set ears, and urogenital anomalies. Since the first case in 1978 [5], about 50 cases of the 3pter-p25 contiguous gene deletion syndrome (MIM 613792) have been reported. The 11.6 Mb deletion in our case contained 65 genes, out of which 27 are OMIM genes such as CNTN4, SETD5, VHL CHL1 SLC6A1 ITPR1, HRH1, ATG7, CRELD1 and MTMR14. Three of these (CNTN4, SETD5 and VHL) were curated by Clingene Dosage Gene Map (retrieved from www.ncbi.nlm.nih.gov/ projects/dbvar/clingen) and were given a high haploinsufficiency score. The SETD5 (SET domain containing 5, MIM 615743) gene encodes a histone methyltransferase highly conserved and expressed in the fetal brain. Heterozygous mutations of SETD5 cause the autosomal dominant mental retardation 23 (MIM 615761) with different dysmorphic features [15]. Mattioli et al. [16] compared three groups of patients; those who had disrupted only BRPF1, both BRPF1 and SETD5, and only SETD5. The authors noted that in patients with disruption of both genes the intellectual disability was more severe, compared to either of these genes. They concluded that BRPF1 haploinsufficiency, as well as the SEDT5 significantly contributed to syndromic intellectual disability (MIM 617333) in a 3p25-phenotype. CNTN4 encodes a member of the immunoglobulin superfamily of neuronal cell adhesion molecules (Contactin 4, MIM 607280) and has a major role in brain development. Fernandez et al. [17] reported a patient with phenotypical features of 3p deletion syndrome which had de novo balanced translocation t(3;10)(p26;q26). This translocation disrupted the CNTN4 gene on the 3p26 region and caused growth retardation, development delay and dysmorphic features. Suzuki-Muromoto et al. [18] reported a patient showing classical phenotypical features of 3p deletion but also exhibiting cerebellar hemangioblastoma, which was diagnosed as VHL syndrome. Array comprehensive genomic hybridization analysis revealed a de novo deletion of the 3p25 region encompassing VHL. Neurodevelopment difficulties are often present in 3p deletion syndrome. Deletion or disruption of CHL1, ITPR1 and SLC6A1 genes could lead to neurodevelopmental difficulties because of their high expression patterns in the brain [19-22]. In approximately one-third of patients, a congenital heart defect (CHD), commonly atrioventricular septal defect, has been reported. Shuib et al. [23] reported a detailed aCGH analysis of 14 patients with 3p deletion syndrome. As well as the typical symptoms of 3p deletion syndrome including neurodevelopment delay and different structural malformations, five patients also exhibited CHD. The authors suggested a candidate critical region for CHD of approximately 200 kb in the region 3p25 containing genes HRH1 and ATG7, although the involvement of the previously proposed CRELD1 gene [24] located distally could not be excluded. Our case had deleted HRH1, ATG7 and CRELD1 but without heart defects suggesting variant penetrance in different cases. CAV3 and MTMR14 were also suggested to contribute to phenotype of 3p deletion syndrome [25,26]. CAV3 (Caveolin 3, MIM 601253) and MTMR14 (Myotubularin-related protein 14, MIM 611089) that encodes a muscle-specific inositide phosphatase, contribute to the development and regulation of muscles. Disruption of the CAV3 gene can lead to different types of skeletal muscle disorders of autosomal dominant mode of inheritance such as familial hypertrophic cardiomyopathy (MIM 192600), hyperCKemia (MIM 123320), Tateyama type of distal myopathy (MIM 614321) and rippling muscle disease (MIM 606072), long QT syndrome 9 (MIM 611818), while disruption of the MTMR14 gene can lead to centronuclear myopathy (MIM 160150). Chen et al. [27,28] reported two prenatal cases with distal 3p deletion. In the first case, cytogenetic and aCGH analysis showed a de novo deletion 3p25.3-pter, including a large number of genes that are involved in neurodevelopment disorders. The pregnancy was terminated at 24 weeks’ gestation and fetal autopsy showed brachicephaly, micrognatia, short and thick nose, together with hypertelorism and low-set ears, which were also present in our case. The second prenatal case showed 3p deletion accompanied with fetoplacental discrepancy [28]. A finding of isolated septated cystic hygroma during the first trimester of pregnancy is associated with chromosomal abnormalities in approximately 50.0% of cases, most commonly numerical chromosomal aberrations, e.g., monosomy X or trisomies 21, 13 and 18 [29]. Structural chromosomal abnormalities are considered as rare findings, detected in approximately 2.5% of such pregnancies [30]. The use of microarray analysis increases the probability of detection of pathogenic CNV to approximately 4.0% in cases of isolated NT and to 7.0% when additional malformations are present [31]. In conclusion, our case emphasizes the value of first trimester NT measurement as a screening method not only for the most common numerical chromosomal abnormalities, but also for rare structural rearrangements. Furthermore, the application of both conventional and molecular cytogenetic methods, are essential for detection and precise delineation of revealed aberrations, enabling detailed genetic counseling regarding present and future pregnancies. Acknowledgments. Authors’ contributions: M. Vulic, S.Z. Tomas and R.G. Juraski contributed to the identifica-tion of the local case; A. Vicic, F. Stipoljev and M. Logara performed the cytogenetic, FISH and aCGH analyses; M. Barbalic, R.G. Juraski and M. Logara drafted the manuscript; F. Stipoljev contributed significantly to the manuscript preparation. All authors read and approved the final manuscript. Declaration of Interest. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.



Number 27
VOL. 27 (2), 2024
Number 27
VOL. 27 (1), 2024
Number 26
Number 26 VOL. 26(2), 2023 All in one
Number 26
VOL. 26(2), 2023
Number 26
VOL. 26, 2023 Supplement
Number 26
VOL. 26(1), 2023
Number 25
VOL. 25(2), 2022
Number 25
VOL. 25 (1), 2022
Number 24
VOL. 24(2), 2021
Number 24
VOL. 24(1), 2021
Number 23
VOL. 23(2), 2020
Number 22
VOL. 22(2), 2019
Number 22
VOL. 22(1), 2019
Number 22
VOL. 22, 2019 Supplement
Number 21
VOL. 21(2), 2018
Number 21
VOL. 21 (1), 2018
Number 21
VOL. 21, 2018 Supplement
Number 20
VOL. 20 (2), 2017
Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006